SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Wanbury expands regulatory submission for launch of new APIs

09 Jun 2026 Evaluate

Wanbury has expanded regulatory submission for launch of new Active Pharmaceuticals Ingredients (APIs). For Diphenhydramine HCl, the company has submitted DMF to Malaysia and Singapore. The company has proposed to explore new market opportunities for Paroxetine HCl in Korea and Latin America by submitting the DMFs. The company has also received formal audit report from MFDS (Korea FDA) for its Patalganga facility stating zero observation for the inspection conducted in April 2026.

Wanbury, one of India’s fastest growing pharmaceutical companies amongst the ‘Top 50 Companies’ in India (as per ORG-IMS), has a strong presence in API global market and domestic branded Formulation.

Wanbury Share Price

259.35 -6.55 (-2.46%)
10-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1787.10
Dr. Reddys Lab 1271.75
Cipla 1376.25
Zydus Lifesciences 1097.90
Lupin 2248.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×